Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
NCT05875701
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
03/01/2024
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Register for Updates
Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults
NCT04502693
Completed
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.
Gender:
ALL
Ages:
Between 10 years and 25 years
Trial Updated:
02/09/2024
Locations: GSK Investigational Site, Laredo, Texas +2 locations
Conditions: Infections, Meningococcal
Register for Updates
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
NCT03486834
Completed
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age. Participants received blinded V160 on Day 1, Month 2, and Month 6 (3-dose regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on Day 1, Month 2, and Month 6, and were followed to approximately Month 24. The primary hypothesis of the study was that administration o... Read More
Gender:
FEMALE
Ages:
Between 16 years and 35 years
Trial Updated:
01/19/2024
Locations: Tekton Research, Inc. ( Site 0036), Austin, Texas +8 locations
Conditions: Cytomegalovirus (CMV) Infections
Register for Updates
Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
NCT03673462
Completed
The primary objective of this study was to describe the safety profile of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate Vaccine and Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 (MENVEO®) Conjugate Vaccine when administered concomitantly with routine pediatric vaccines in healthy infants and toddlers.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
12/11/2023
Locations: ARC Clinical Research at Wilson Parke-Site Number:8400071, Austin, Texas +4 locations
Conditions: Healthy Volunteers (Meningococcal Infection)
Register for Updates
A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD
NCT03734237
Active Not Recruiting
A total of 18,000 eligible subjects (or 6,000 subject distributed evenly between the 3 study arms) will be enrolled. Eligible subjects will be randomized in 1:1:1 (cell-culture-based vaccine, the recombinant vaccine, or the egg-based vaccine) over four influenza seasons (2018-2019, 2019-2020, 2020-2021, and 2021-2022).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2023
Locations: Brooke Army Medical Center, Fort Sam Houston, Texas +1 locations
Conditions: Influenza, Influenza-like Illness, Influenza Vaccines
Register for Updates
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
Completed
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
11/13/2023
Locations: Coastal Bend Clinical Research, Corpus Christi, Texas +8 locations
Conditions: Pneumococcal Disease
Register for Updates
Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older
NCT06118151
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different dose levels of messenger ribonucleic acid (mRNA) vaccine encoding influenza hemagglutinin compared to an active control quadrivalent recombinant influenza vaccine (RIV4) in adults 18 years of age and older. Study details include: Study Duration: approximately 6 months Treatment Duration: 1 injection of mRNA vaccine encoding influenza hemagglutinin encoding influenza hemag... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: Elligo Health Research, Inc. Site Number : 8400035, Austin, Texas +3 locations
Conditions: Influenza, Influenza Immunization
Register for Updates
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
NCT05047770
Completed
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu D-QIV) vaccine in healthy adults 18 YOA and older, when administered sequentially or co-administered with Moderna's mRNA-1273 booster vaccination against COVID-19.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: GSK Investigational Site, Beaumont, Texas +4 locations
Conditions: Herpes Zoster
Register for Updates
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
NCT03739112
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 206) Benchmark Research, Austin, Texas +5 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
NCT01964989
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 208, Novartis Investigational Site, Austin, Texas +5 locations
Conditions: Influenza Virus
Register for Updates
A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)
NCT04168190
Completed
This Phase 1 and Phase 2 study will evaluate the safety, tolerability and immunogenicity of V116 when administered to adults. Phase 1 has no formal hypothesis. The primary hypotheses for Phase 2 are: V116 is noninferior to Pneumovax™23 as measured by the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) for the common serotypes at 30 days postvaccination and that the serotype-specific OPA GMTs for the unique serotypes in V116 at 30 days postvaccination are statistica... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2022
Locations: Diagnostics Research Group ( Site 0013), San Antonio, Texas
Conditions: Pneumonia, Pneumococcal
Register for Updates
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590
Completed
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2 month schedule, in older adults aged 60 to 80 years. As the investigational vaccines have not yet been tested in humans before, the study will first assess the safety, reactogenicity and immune responses in young adults aged 18 to 40 years. The study will thus be conducted... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/04/2022
Locations: GSK Investigational Site, Fort Worth, Texas +2 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates